Heart Failure
Conditions
Brief summary
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates plasma glucose, and GLP-1 analogues were recently introduced for the treatment of acute myocardial infarction. The investigators planned to evaluate the effects of liraglutide on haemodynamic parameters in patients with heart failure.
Detailed description
Heart failure (HF) is a major cause of morbidity and mortality world wide. Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates plasma glucose, and has direct effects on the cardiovascular system. In our previous study, the GLP-1 analogue liraglutide could improve left ventricular function in patients with non-ST-segment elevation myocardial infarction. However, the effects of GLP-1 on HF patients remain unclear. Pulse indicator continuous cardiac output (PiCCO) technology is a combination of transpulmonary thermodilution and pulse contour analysis, which measures hemodynamic variables (left ventricular ejection fraction, volumes, and mass) in a fast and feasible way. Therefore, the aim of this study was to evaluate the effects of liraglutide on hemodynamic variables in HF patients using the PiCCO system.
Interventions
DRUGliraglutide
Liraglutide were taken daily for 7 days
DRUGplacebo
Placebo were taken daily for 7 days
Sponsors
Chinese PLA General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Patients with HF were eligible for the study. Diagnosis of HF was based on an impaired ejection fraction (\<50%).
Exclusion criteria
Patients were also excluded for the following reasons: unconscious at presentation; valvular heart disease, cardiogenic shock, hypoglycaemia, or diabetic ketoacidosis; or renal insufficiency.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| a change in cardiac output measured by pulse indicator continuous cardiac output (PiCCO) technology | 7 days after treatment | The primary efficacy endpoint was the effect of liraglutide on cardiac output (CO) at 7 days compared with placebo. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| a change in left ventricular contractile index measured by PiCCO technology | 7 days after treatment | The change in left ventricular contractile index was measured at 7 days after treatment. |
Countries
China
Contacts
Primary ContactWei Ren Chen, M.D.
Outcome results
None listed